Literature DB >> 16191093

Splenectomy for adult chronic idiopathic thrombocytopenic purpura: experience from a single center in China.

Tingting Wang1, Maoqiang Xu, Linxiang Ji, Zhong Chao Han, Renchi Yang.   

Abstract

OBJECTIVES: The aim of this study was to explore the results of Chinese chronic idiopathic thrombocytopenic purpura (ITP) patients who underwent splenectomy (SE). SUBJECTS AND METHODS: Data of 149 chronic ITP patients were retrospectively analyzed. Relapse-free survival was estimated by Kaplan-Meier analysis. Differences between responders and non-responders were evaluated using the chi-square.
RESULTS: The immediate response rate was 82.6% and the sustained response rate was 63.1%. Twenty-nine patients (19.5%) relapsed during follow-up. The 5-year actuarial relapse-free survival was about 75%. The overall morbidity was 26.1% and mortality was 2.7%. Patients with higher postsplenectomy peak platelet count, shorter time from diagnosis to SE and previous response to IVIG therapy were more likely to have sustained response to SE.
CONCLUSION: SE is potentially a useful therapy to provide long-term control of disease in adults with chronic ITP and is associated with low morbidity and mortality. Postsplenectomy peak platelet count, time from diagnosis to SE and previous response to intravenous immune globulin therapy appear predictive for response to SE.

Entities:  

Mesh:

Year:  2005        PMID: 16191093     DOI: 10.1111/j.1600-0609.2005.00517.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

1.  Long-term outcomes of a 5-year follow up of patients with immune thrombocytopenic purpura after splenectomy.

Authors:  Jae Joon Han; Sun Kyung Baek; Jae Jin Lee; Si-Young Kim; Kyung Sam Cho; Hwi-Joong Yoon
Journal:  Korean J Hematol       Date:  2010-09-30

2.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

3.  Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China.

Authors:  Mingjun Rui; Yingcheng Wang; Zhengyang Fei; Ye Shang; Aixia Ma; Hongchao Li
Journal:  Front Med (Lausanne)       Date:  2021-03-18

Review 4.  Management of immune thrombocytopenia: 2022 update of Korean experts recommendations.

Authors:  Young Hoon Park; Dae-Young Kim; Seongkoo Kim; Young Bae Choi; Dong-Yeop Shin; Jin Seok Kim; Won Sik Lee; Yeung-Chul Mun; Jun Ho Jang; Jong Wook Lee; Hoon Kook; On Behalf Of Korean Aplastic Anemia Working Party
Journal:  Blood Res       Date:  2022-03-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.